Retrophin, Inc. (NASDAQ:RTRX) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday, August 4th.
A number of other analysts also recently issued reports on RTRX. TheStreet raised shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. William Blair reissued an “outperform” rating on shares of Retrophin in a report on Thursday, April 6th. Finally, Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $32.25.
Retrophin (NASDAQ:RTRX) traded up 0.93% during trading on Friday, reaching $23.86. 416,535 shares of the company were exchanged. The company’s 50-day moving average price is $20.41 and its 200-day moving average price is $19.18. The stock’s market capitalization is $915.87 million. Retrophin has a 1-year low of $15.55 and a 1-year high of $24.57.
In other news, COO Neil F. Mcfarlane sold 1,378 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares in the company, valued at $306,495. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.41% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Retrophin during the first quarter worth approximately $185,000. Point72 Asset Management L.P. boosted its stake in shares of Retrophin by 133.8% in the first quarter. Point72 Asset Management L.P. now owns 964,800 shares of the biopharmaceutical company’s stock worth $17,810,000 after buying an additional 552,065 shares during the period. Virginia Retirement Systems ET AL boosted its stake in shares of Retrophin by 99.2% in the first quarter. Virginia Retirement Systems ET AL now owns 75,100 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 37,400 shares during the period. FMR LLC boosted its stake in shares of Retrophin by 24.8% in the first quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock worth $36,161,000 after buying an additional 389,714 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Retrophin during the fourth quarter worth approximately $387,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.